Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 14/20 | 0.66 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | CASP7 | P55210 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22608878 | 0.80 | RIPK1 (0.67) | RIPK1VCPATRSLC6A9KDM4E | |
| SCHEMBL21783469 | 0.80 | RIPK1 (0.67) | RIPK1VCPATRSLC6A9KDM4E | |
| SCHEMBL22608879 | 0.80 | RIPK1 (0.67) | RIPK1VCPATRSLC6A9KDM4E | |
| SCHEMBL20165777 | 0.80 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL20165776 | 0.80 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL25691671 | 0.74 | RIPK1 (0.61) | RIPK1VCPATRKDM4EMEN1 | |
| SCHEMBL25801153 | 0.73 | RIPK1 (0.68) | RIPK1 | |
| SCHEMBL22608875 | 0.70 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL22608876 | 0.70 | RIPK1 (0.54) | RIPK1 | |
| SCHEMBL22608945 | 0.70 | RIPK1 (0.54) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4665334-A1 | TRIPLE KINASE INHIBITION FOR THE TREATMENT OF TYPE I INTERFERON RESPONSE ASSOCIATED DISORDERS | Universität zu Köln (DE) | 2025-12-24 | — | — | EP | claimed |
| WO-2024170776-A1 | TRIPLE KINASE INHIBITION FOR THE TREATMENT OF TYPE I INTERFERON RESPONSE ASSOCIATED DISORDERS | UNIVERSITÄT ZU KÖLN (DE) | 2024-08-22 | — | — | WO | claimed |
| EP-4665334-A1 | TRIPLE KINASE INHIBITION FOR THE TREATMENT OF TYPE I INTERFERON RESPONSE ASSOCIATED DISORDERS | Universität zu Köln (DE) | 2025-12-24 | — | — | EP | disclosed |
| WO-2024170776-A1 | TRIPLE KINASE INHIBITION FOR THE TREATMENT OF TYPE I INTERFERON RESPONSE ASSOCIATED DISORDERS | UNIVERSITÄT ZU KÖLN (DE) | 2024-08-22 | — | — | WO | disclosed |
| WO-2023122298-A1 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP28 AND/OR USP25 TARGETING LIGANDS | Stablix, Inc. (US) | 2023-06-29 | — | — | WO | disclosed |